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Aminoglycosides for Intra-Abdominal Infection:
Equal to the Challenge?
JEFFREY A. BAILEY,1 KATHERINE S. VIRGO,1 JOSEPH T. DIPIRO,2 AVERY B. NATHENS,3
ROBERT G. SAWYER,4 and JOHN E. MAZUSKI1

ABSTRACT
Background: Aminoglycosides, combined with antianaerobic agents, have been used widely
for the treatment of intra-abdominal infection. However, some prospective randomized controlled trials and other data suggested that aminoglycosides were less efficacious than newer
comparators for the treatment of these infections. We therefore performed a meta-analysis of
all prospective randomized controlled trials utilizing aminoglycosides to reevaluate the efficacy of these agents for the treatment of intra-abdominal infection.
Methods: Published English-language prospective randomized controlled trials comparing
aminoglycosides with other agents for treatment of intra-abdominal infection were identified
by MEDLINE search. For each study, data were collected regarding the number of patients
enrolled and evaluated, their basic demographic characteristics, the sources of the intra-abdominal infections, the number of failures as determined by the study investigators, quality
score, and the use of serum drug concentrations to monitor aminoglycoside therapy. These
data were combined to calculate odds ratios for risk of therapeutic failure, which were assessed for significance using Chi-square analysis.
Results: Forty-seven prospective randomized controlled trials comparing aminoglycosides
to other agents were identified. These were published between 1981 and 2000, and included
a total of 5,182 evaluable patients. Analysis of all studies combined revealed an odds ratio
that slightly, but significantly, favored the comparators. After excluding six trials using comparators that lacked accepted antianaerobic efficacy, the odds ratio more strongly favored comparators. Trials published since 1990 also notably favored comparators. Analyzing results by
quality score or the use of aminoglycoside monitoring did not alter these findings.
Conclusions: In this meta-analysis, aminoglycosides were less efficacious than newer comparators for the treatment of intra-abdominal infection. Given the well-known toxicities of
these agents, we conclude that they should not be used as first-line therapy for these infections.
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with antianaerobic agents were the first antimicrobial regimens recognized as efficacious for the
treatment of patients with intra-abdominal infection. Some still consider this regimen to be
the gold standard of antimicrobial therapy for
these infections. However, aminoglycosides
have substantial nephrotoxicity and ototoxicity. In addition, they require monitoring of
serum concentrations for optimal utilization.
Thus, other agents with equal efficacy that do
not exhibit such toxicity or need intensive monitoring might be more desirable for the treatment of patients with intra-abdominal infections.
A large number of prospective randomized
controlled trials have compared the efficacy of
aminoglycosides against newer antimicrobials
to identify such alternative regimens. A few of
these trials actually demonstrated greater efficacy of the comparator agents, calling into
question the continued use of aminoglycosides
as first-line agents for the treatment of intra-abdominal infections [1]. However, nearly all trials were designed only to detect therapeutic
equivalence, which allows for differences in efficacy as high as 15–20% between regimens;
very few, if any, of the trials were actually powered to detect therapeutic superiority. Thus, the
appropriate role of aminoglycosides in the
treatment of intra-abdominal infection is difficult to ascertain on the basis of the individual
study data.
Meta-analysis provides a tool with which to
aggregate the results of smaller, individual trials, such that statistical analysis may be applied
to answer questions that these individual studies cannot address [2–5]. In order to re-evaluate the role of aminoglycosides in the treatment
of intra-abdominal infections, we performed a
meta-analysis of all prospective randomized
controlled trials that compared aminoglycoside-based regimens against agents from other
antibiotic classes for the treatment of these infections. We hypothesized that these combined
data might make it possible to more definitively answer the question as to whether or not
aminoglycoside-based regimens should still be
considered first-line agents for the treatment of
patients with intra-abdominal infections.
MINO GLYCOSIDES IN COMBINATION

MATERIALS AND METHODS
Study identification and selection
All published English-language prospective
randomized controlled trials that compared an
aminoglycoside in combination with an antianaerobic agent against antimicrobials from
other classes for the treatment of patients with
established intra-abdominal infections were selected for potential inclusion in the meta-analysis. Results available only in abstract form were
not included in this analysis, because most
studies on aminoglycoside use were performed
more than five years ago, and it was not likely
that such trials could be identified and evaluated systematically. Published trials were identified from a search of the MEDLINE database
using the names of specific aminoglycosides
paired with words and phrases suggesting an
intra-abdominal infection (such as peritonitis,
intra-abdominal abscess, appendicitis). This
search strategy was supplemented by examination of the references found in various articles discussing treatment of intra-abdominal
infections, and also by a search of the Cochrane
database.
Published studies identified by this initial
search strategy were then excluded for a variety of reasons. Studies were not considered
further if the data had not been acquired
prospectively, or if the subjects had not been
randomized. Studies designed to evaluate prophylactic use of antimicrobials for surgical
procedures not involving intra-abdominal infections were also excluded, including those
involving patients undergoing elective abdominal procedures as well as those having
acute intraperitoneal contamination. Trials
that included subjects with infections outside
the abdominal cavity were excluded unless the
results were reported separately for patients
with intra-abdominal infections. Finally, trials
in which patients received an antimicrobial in
addition to an aminoglycoside that was effective against gram-negative aerobic/facultative
anaerobic bacteria were eliminated, unless that
additional antibiotic was ampicillin or penicillin being provided for enterococcal coverage.
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Data abstraction and assessment
The resultant trials were reviewed, and data
were abstracted with regard to year of publication, total number of patients enrolled, number
of evaluable patients, demographics of evaluable patients, patient diagnoses or anatomic
sources of intra-abdominal infection, the specific aminoglycoside and comparator regimens
used, number of treatment failures as identified by the individual study investigators, the
use of serum drug levels to monitor aminoglycoside therapy, and toxicity due to antimicrobials. Quality scores were determined using the
method of Jadad et al. [6]. Scores ranged from
zero to five, with five representing the highest
quality score that could be achieved (Table 1).
All quality scores were determined independently by at least two investigators.
Statistical analysis
Risks of therapeutic failure with aminoglycoside-based therapies relative to risks of therapeutic failure with comparator therapies were
expressed as odds ratios. An odds ratio less
than one favored the aminoglycoside-based
regimens, whereas an odds ratio greater than
one favored the comparator agents. Confidence
intervals were derived for these ratios, with
Chi-square analysis being used to establish statistical significance. Odds ratios, P values, and
95% confidence intervals were determined for
each individual trial, for all trials combined,
and for trials grouped by year of publication,
comparator class, quality score, percentage of
subjects with appendiceal disease, use of
TABLE 1.

QUALITY SCORING SYSTEM

Give one point if the study was randomized, and:
Give one additional point if the method of randomization was appropriate
Deduct one point if the method of randomization
was inappropriate
Give one point if the study was double blinded, and:
Give one additional point if the method of blinding
was appropriate
Deduct one point if the method of blinding was
inappropriate
Give one point if there was a description of
withdrawals and dropouts
From Jadad et al. [6].
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aminoglycoside monitoring, and enrollment of
pediatric patients [7,8].
To assess trial heterogeneity, the procedure
outlined by L’Abbe et al. was utilized [4]. Predicted failure rates for aminoglycosides and
comparators were determined by linear regression analysis of all trials, and 95% confidence limits about this derived relationship
were determined. Individual trial results were
then plotted to determine the number of trials
with results outside of those confidence intervals.
RESULTS
Trial and patient characteristics
The initial search strategy identified 112 trials, of which 65 [9–73] were excluded from further analysis for the reasons given in Table 2.
Data from 47 publications were included in the
meta-analysis [74–120]. Two studies included
three treatment arms, one of which involved an
aminoglycoside-based regimen [74,76], and
one other study had four separate treatment
arms, two of which involved an aminoglycoside-based regimen [84]. These trials were published between 1981 and 2000. A total of 7,772
patients were enrolled in the trials, with the
number of patients enrolled in individual trials ranging from 41 to 993. Of these 7,772 patients, 5,182 (66%) were clinically evaluable by
individual study criteria. The number of clinically evaluable patients in these trials ranged
from 28 to 341.
Study enrollment criteria included known or
suspected intra-abdominal infection based on
physical, laboratory, and radiographic examinations, and findings at the time of operative
or other interventional procedures. Enrollment
criteria usually required the patient to have undergone a source control procedure by the operative or percutaneous route. In fact, only nine
clinically evaluable patients were specifically
identified as having undergone medical therapy only. These patients would not have been
considered to have had “complicated” intra-abdominal infection as defined by the criteria of
Solomkin et al. [121].
Exclusion criteria varied from study to study.
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TABLE 2.

REASONS

FOR

TRIAL EXCLUSION

Design did not test an aminoglycoside plus an
antianaerobic agent against another comparator
regimen [9–26]
Included patients with infections outside the
abdominal cavity, and did not separately tabulate
results for patients with intra-abdominal infection
[27–40]
Primarily evaluated the use of prophylactic, not
therapeutic antimicrobial therapy [41–54]
Not a prospective, randomized controlled trial on
detailed review [55–67]
Data available only in abstract form [68, 69]
Clinical outcomes not documented [70]
Limited number of patients with intra-abdominal
infection [71]
Intraperitoneal antimicrobial therapy [72]
German language publication [73]

Most trials excluded patients outside of specific
age ranges, in order to prevent enrollment of
children in adult studies and vice versa. However, two trials specifically excluded patients of
advanced adult age [78,102]. The most common
exclusion criteria were pregnancy or lactation,
previous hypersensitivity to trial antimicrobial
agents, recent or concurrent treatment with antimicrobials, infection with organisms known
to be resistant to study agents, and concurrent
participation in other clinical trials. Many
studies excluded moribund patients, those not
expected to survive 48 hours, and those with
terminal illnesses. Patients with high-acuity illness, immunosuppression HIV disease, granulocytopenia, and renal or hepatic dysfunction
or failure were variably excluded.
Definitions of success and failure varied
from study to study. Cure was generally defined as resolution of all clinical signs of infection without the need for additional antimicrobial therapy or operative intervention.
Several studies also included a final outcome
defined as improved, in which there was control of the primary infective process, but with
some form of ongoing clinical disability. For
this meta-analysis, patients classified as improved were considered to be treated successfully. Definitions of treatment failure varied
somewhat more widely between studies. Patients who died as a result of their infections or
who required additional antimicrobials or procedures, including drainage of wound infec-

tions, to control their infectious process were
generally considered to have failed treatment.
However, patients who developed adverse reactions to study medications, who developed
infectious complications outside of the abdominal cavity, or who died as a result of other disease processes were variously reported as treatment failures, unevaluable, or occasionally as
treated successfully.
Thirty-three of the 47 studies, including 78%
of the evaluable patient population, provided
demographic information. Sixty-seven percent
of these patients were male. The reported age
range was from 6 months to 91 years. In trials
enrolling only adult patients, the mean age was
40 years. Six trials enrolled pediatric patients
only [84,91,96,101,105,106], and one additional
trial included a subset of pediatric patients [86].
In all, 688 of the characterized patients were in
the pediatric age range. Thus, pediatric patients
represented at least 13% of the total population
of clinically evaluable patients.
Among the studies providing adequate information, the most prevalent source of intraabdominal infection was the appendix. A total of 2,621 patients were described as having
appendiceal disease, representing at least 51%
of all clinically evaluable patients. Of these
2,621 patients, 2,126 (81%) were identified as
having complicated appendicitis (gangrenous,
perforated, or abscessed) and 495 were listed
as having appendicitis, but not otherwise described. In all six of the studies enrolling pediatric patients exclusively, the appendix was
the anatomic source of the infection. Other
commonly reported diagnoses or sources of intra-abdominal infection are listed in Table 3.
Randomization of patients resulted in 2,451
being assigned to aminoglycoside-based therapy and 2,731 to comparator therapy. Aminoglycosides tested were primarily gentamicin or
tobramycin, with netilmicin and amikacin being used in a few trials (Table 4). The antianaerobic agent used most commonly with
the aminoglycoside was clindamycin, although
metronidazole was used in several trials. In
seven treatment groups, concomitant treatment
with penicillin or ampicillin was required or
permitted.
A variety of comparator regimens were employed (Table 5). Twenty-two treatment
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TABLE 3.

DIAGNOSIS

OR

SOURCE

OF

INTRA-ABDOMINAL INFECTION

Source or diagnosis

Number of patients

Appendix (total)
Complicated appendicitis (perforated, gangrenous, abscessed)
Appendicitis (not otherwise specified)
Intra-abdominal abscess
Hepatobiliary
Peritonitis (not otherwise specified)
Gastroduodenal perforation
Perforated viscus (not otherwise specified)
Large bowel perforation
Diverticular disease
Small bowel perforation
Miscellaneous (not otherwise specified)
Other diagnoses

groups received cephalosporins, with or without additional antianaerobic agents, nine received carbapenems as monotherapy, and nine
received penicillins with or without beta-lactamase inhibitors. Other regimens tested included aztreonam in combination with clindamycin, the oxa-beta-lactam agent moxalactam,
and the fluoroquinolone pefloxacin in combination with metronidazole.
Study quality varied widely, but tended to
be low. Quality scores ranged from 0 to 5, with
the mean score being two. The distribution of
quality scores is indicated in Figure 1.
Outcome analysis
Efficacy. Odds ratios (OR) with 95% confidence intervals (CI) were recalculated for
each trial individually. The results of this

TABLE 4.

AMINOGLYCOSIDE -BASED REGIMENS

Agents
Aminoglycosides
Gentamicin
Tobramycin
Gentamicin or tobramycin
Netilmicin
Amikacin
Antianaerobic and other agents
Clindamycin
Clindamycin or metronidazole
Metronidazole
Clindamycin plus ampicillin
Clindamycin plus penicillin
Metronidazole plus ampicillin
Metronidazole plus penicillin
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Number of
treatment arms
26
15
1
4
2
35
1
4
3
1
2
1

2,621
2,126
495
369
354
302
290
184
243
100
97
173
208

analysis are presented in Figure 2, with trials
organized by date of publication. An odds ratio of less than one indicated that the trial favored the aminoglycoside-based regimen,
whereas an odds ratio of greater than one favored the comparator regimen. Differences
between the treatment arms were statistically
significant only in those studies in which the
confidence interval did not include the value
one. Odds ratios could not be established in
four studies in which a 100% success rate was
reported for either the aminoglycoside or
comparator arm [74,92,110,120]. Five studies
demonstrated statistically significant differences in outcome [76,95,96,99,120], with two
favoring the aminoglycoside-based regimen
[76,120], and three favoring the comparator
regimen [95,96,99]. One study [114] reported
statistical significance in favor of the comparator regimen using logistic regression
analysis, but this was not evident using simple Chi-square analysis.
Initial meta-analysis of data from all 5,182
patients revealed an OR of 1.194 (CI 1.014–
1.407, P 5 0.04), which slightly, but significantly, favored the comparator regimens. In reviewing the individual odds ratios, however, it
appeared that trials published prior to 1990
were more likely to show therapeutic equivalence, whereas subsequent trials more consistently favored comparator regimens. Pooled
data were therefore analyzed separately for trials published prior to 1990 and for those published in 1990 and later. Although no statistical difference was observed in the aggregate
data published prior to 1990, the results of tri-
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TABLE 5.

COMPARATOR REGIMENS

Agents

Number of
treatment arms

Cephalosporins
Cephalothin (monotherapy)
Cefamandole (monotherapy)
Cefoxitin (monotherapy)
Cefotetan (monotherapy)
Cefminox (monotherapy)
Cefotaxime (monotherapy)
Cefotaxime plus metronidazole
Cefoperazone (monotherapy)
Cefoperazone plus sulbactam
Cefoxatime plus clindamycin
Ceftriaxone (monotherapy)
Ceftriaxone plus metronidazole
Ceftazidime plus clindamycin
Cefipime plus metronidazole
Carbapenems:
Imipenem/cilastatin
Meropenem
Penicillins
Ampicillin/sulbactam
Amoxicillin/clavulanate
Ticarcillin/clavulanate
Piperacillin/tazobactam
Piperacillin
Aztreonam plus clindamycin
Moxalactam
Pefloxacin plus metronidazole

22
1
2
4
2
1
1
1
1
2
1
1
1
1
1
9
6
3
9
2
1
3
2
1
4
3
1

als published from 1990 on more strongly favored the comparator regimens (OR 1.438, n 5
3,169, CI 1.165–1.775, P 5 0.001; Fig. 3).
Six early trials [74,76,83,91,109,115] employed comparator regimens that lacked ad-

FIG. 1.

equate anaerobic coverage according to contemporary standards [122]. These trials utilized cephalothin, cefamandole, cefotaxime,
cefoperazone, or ceftriaxone as monotherapy.
The data were therefore reanalyzed after excluding these six trials. A much greater risk
of therapeutic failure for the aminoglycosidebased regimens was observed in this reanalysis (OR 1.296, n 5 4,446, CI 1.085–1.547,
P 5 0.004; Fig. 4).
Data were also analyzed according to the
class of comparator utilized (Fig. 5). Fluroquinolones were not analyzed because only
one trial employed these agents. Subset analysis indicated that cephalosporins (OR 1.94, n 5
1,426, CI 1.689–2.230, P 5 0.005), carbapenems
(OR 1.49, n 5 994, CI 1.296–1.712, P 5 0.03),
and moxalactam (OR 2.24, n 5 313, CI
1.944–2.578, P 5 0.002) were favored over the
aminoglycoside-based regimens. Azetreonam
was also favored over aminoglycosides (OR
1.036, n 5 511, CI 0.901–1.190), but this difference did not reach statistical significance. The
odds ratio favored aminoglycoside-based regimens compared to regimens utilizing any type
of penicillin (OR 0.91, n 5 1,060, CI 0.792–
1.046), but this difference was also not statistically significant. The trend in favor of aminoglycosides appeared to be due to studies utilizing ampicillin/sulbactam or amoxicillin/
clavulanate; when studies using these latter
agents were excluded, the odds ratio signifi-

Distribution of quality scores.
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FIG. 2. Odds ratios for individual trials. Odds ratios could not be calculated for four trials [74,92,110,120] because
the failure rate was zero in the aminoglycoside or comparator arm. Of these studies, that by Yellin et al. [120] demonstrated statistical significance in favor of the aminoglycoside-based regimen. *P , 0.05 by two-tailed test; **P , 0.05
by logistic regression analysis carried out in original trial, but not when recalculated by Chi square analysis.

cantly favored the remaining extended spectrum penicillins (OR 1.18, n 5 808, CI 1.027–
1.357, P 5 0.002).
Study quality did not appear to have a major influence on the finding that comparator
regimens were generally favored over aminoglycoside-based regimens. Trials were separated into two aggregates based on a quality
score of less than or equal to two versus three
or greater. In both subsets, the odds ratios favored the comparator agents, although this was
statistically significant only for the subset with
lower quality scores (quality score # 2, OR

1.26, n 5 2,776, CI 1.007–1.576, P 5 0.05; quality score $ 3, OR 1.116, n 5 2,406, CI 0.877–
1.420, P 5 ns; Fig. 6).
Since the appendix was the source of the infection in greater than 50% of patients for
whom information was provided, a subset
analysis was performed to determine if this influenced the results of this meta-analysis (Fig.
7). Forty trials provided sufficient information
to allow separation into subsets based on the
number of clinically evaluable patients who
had appendiceal-related infections. Fifteen trials [76–79,84,91,93,96,97,101,105–107,110,120]

FIG. 3. Odds ratio for all studies and for studies stratified according to year of publication. For all studies P 5 0.04;
for those published prior to 1990 P 5 ns; and for those published from since 1990 on P 5 0.001.
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FIG. 4. Odds ratio for all studies and for studies remaining after elimination of those judged to have inadequate
anaerobic coverage in the comparator arms. For all studies P 5 0.04; for studies remaining after elimination of comparators with inadequate anaerobic efficacy P 5 0.001.

enrolled patients with appendicitis exclusively.
In these trials, the OR favored the aminoglycoside-based regimens, although this did not
reach statistical significance (OR 0.83, n 5
1,108, CI 0.582–1.078, P 5 ns). In a second set
of seven trials [75,89,103,108,116–118], greater
than 50% of the patients had the appendix as
the source of their infection, although the trials
were not limited to patients with appendicitis.

In this subset, only a very slight advantage was
observed for the comparator-based regimens
(odds ratio 1.060, n 5 888, CI 0.844–1.303, P 5
ns). However, in the remaining studies in
which fewer than 50% of the enrolled patients
had the appendix as the source of their infections [81,85,87,88,90,92,94,98–100,104,109,110,
112,114,115,119], the comparator agents were
significantly favored over aminoglycosides

FIG. 5. Odds ratios for studies grouped according to class of comparator. For carbapenems P 5 0.03; for
cephalosporins P 5 0.005; for any penicillins with or without beta-lactamase inhibitors (PCN/B) P 5 ns; for penicillin/beta lactamase inhibitor combinations remaining after eliminating regimens utilizing ampicillin/sulbactam or
amoxicillin/clavulanate (extended spectrum PCN/B) P 5 0.002; for the monobactam P 5 ns; and for the oxa-betalactam P 5 0.002.

AMINOGLYCOSIDES FOR INTRA-ABDOMINAL INFECTION
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FIG. 6. Odds ratios for studies stratified by quality scores. For studies with quality scores of three or greater P 5
ns; for studies with quality scores of two or less P 5 0.05.

(OR 1.399, n 5 2,704, CI 1.133–1.728, P 5 0.002).
Thus, the source of the infection did appear to
influence the results, with comparators being
more strongly favored in trials involving larger
numbers of patients with diagnoses other than
appendicitis.
In 33 of the 47 studies, some monitoring of
serum aminoglycoside concentrations was undertaken, although the manner in which this
was used to adjust aminoglycoside dosing was

not described in many articles. Trials were
stratified according to whether or not serum
drug monitoring was performed. Odds ratios
favored comparators in both subsets, although
these ratios did not reach statistical significance
in either subset (group in which serum concentrations were monitored: OR 1.197, n 5 3,670,
CI 0.990–1.448, P 5 ns; group not monitored:
OR 1.190, n 5 1,512, CI 0.864–1.641, P 5 ns.).
A separate analysis was also carried out on

FIG. 7. Odds ratios for studies stratified according to the source of infection. For studies including only patients
with appendicitis and those in which greater than 50% of the patients had appendicitis P 5 ns; for studies in which
less than 50% of the patients had appendicitis P 5 0.002.
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FIG. 8. Test of heterogeneity. The linear regression line for predicted rates of therapeutic failures with aminoglycoside-based regimens and comparator regimens, and the 95% confidence interval about this regression line are indicated. Data points indicate all individual studies.

the six trials that enrolled pediatric patients exclusively [84,91,96,101,105,106]. In this analysis,
comparators were very slightly favored, but
this difference was not significant.
Heterogeneity. Study heterogeneity was assessed by comparing actual and predicted rates
of therapeutic failure for aminoglycoside-based
and comparator regimens. As shown in Fig. 8,
nearly two-thirds of the actual results reside
outside of the predicted confidence interval, indicating significant heterogeneity of treatment
effects among the various trials.
Aminoglycoside toxicity. Forty-two trials explicitly reported on nephrotoxicity, although
definitions varied widely and occasionally
were not described at all. Among these 42 trials, nephrotoxicity occurred in 98 patients, an
incidence of 2.3%. Seventy of these patients
were from trials that utilized some form of
aminoglycoside monitoring, and 28 of these patients were from trials that did not report such

monitoring. The incidences of nephrotoxicity in
these two subsets were not statistically different by Chi square analysis.
There were only five trials involving 490
aminoglycoside-treated patients that reported
explicitly on ototoxicity. Among these trials, six
patients were found to have ototoxicity, an incidence of 1.2%. Five of these patients developed auditory toxicity, and one developed
vestibular toxicity. Only two trials specifically
described the use of some form of auditory
monitoring or assessment by audiometry to detect ototoxicity. Two patients (0.9%) developed
ototoxicity as a result of aminoglycoside exposure in those trials.

DISCUSSION
Effective treatment of intra-abdominal infection requires adequate drainage of peritoneal suppuration and optimally, definitive
surgical control of infective foci. As adjuncts

AMINOGLYCOSIDES FOR INTRA-ABDOMINAL INFECTION

to operative or percutaneous drainage, the
role of antimicrobials is to limit the persistence
of remaining infectious microorganisms. Antimicrobial therapy is given empirically, and
culture results, even when obtained, rarely
influence therapeutic choices or results. To
be effective, antimicrobials must have activity
against both the aerobic/facultative anaerobic
bacteria and strictly anaerobic organisms
found with intra-abdominal infections. Antimicrobial regimens that do not target both Escherichia coli and Bacteroides fragilis increase the
risk of clinical treatment failure [122].
An aminoglycoside in combination with an
antianaerobic agent was the first regimen generally recognized as efficacious in the treatment
of intra-abdominal infection [122]. This combination is also relatively inexpensive. However,
the ototoxicity and nephrotoxicity of aminoglycosides raise concerns. Routinely, serum
drug concentrations are monitored to avoid
toxicity and improve efficacy of these agents.
However, even with careful monitoring of
serum drug concentrations, aminoglycosides
can still have significant toxic effects. The costs
associated with pharmacokinetic surveillance
as well as those associated with adverse effects
may cancel out any cost savings that these
agents appear to offer [123,124].
Since the first use of aminoglycosides for intra-abdominal infection, several newer antimicrobials effective against aerobic/facultative
anaerobic gram-negative bacilli have become
available. These agents include carbapenems, a
number of second-, third- and fourth-generation cephalosporins, newer extended-spectrum
penicillins (many times combined with betalactamase inhibitors) oxa-beta-lactams, monobactams, and fluoroquinolones. These agents
have been compared to aminoglycosides for
the treatment of patients with intra-abdominal
infection in many prospective randomized controlled trials. Virtually all of these trials have
demonstrated therapeutic equivalence of these
newer comparators with aminoglycosides. A
few have identified statistically significant differences in endpoints, some in favor of aminoglycosides and some in favor of comparator
agents [123]. Particularly in the light of these
latter studies, some have questioned the therapeutic role of aminoglycoside regimens as first-
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line agents for the treatment of patients with
intra-abdominal infections. However, despite
the large number of studies that have been carried out, the data from individual trials are inadequate to make this assessment definitively.
Meta-analysis provides a means to perform
a structured and quantitative evaluation of the
published literature and other studies addressing a specific clinical issue. This technique of mathematically pooling data from
multiple trials may provide answers to questions when prior studies have shown conflicting or insignificant results, usually because of
an inadequate sample size. In the present investigation, meta-analysis revealed a slight,
but significant advantage to comparator agents
compared to aminoglycoside-based regimens
for the therapy of intra-abdominal infections.
Although in theory, the quantitative aspects
of the meta-analytic tool may surpass the limitations of individual trials, in practice the reliability of the final product may be compromised by faulty design of the meta-analytic
study itself as well as by poor quality of the individual data being pooled [1–5,125–127]. With
regard to the quality of the pooled data, we
sought to use the best evidence available for
this analysis. This should be found in prospective randomized controlled trials published in
peer-reviewed literature. In order to avoid inadvertent exclusion of relevant data, we utilized multiple overlapping search strategies to
identify all publications that met our inclusion
criteria, and only eliminated studies after they
were reviewed fully.
For this meta-analysis, the few reports published in abstract form and unpublished data
were not included as they tended to be quite
old. We did not believe that this small amount
of additional information was likely to be representative and unbiased, and was unlikely to
influence appreciably the overall results. Due
to limited resources it was not possible to review potentially useful prospective randomized controlled trials published in languages
other than English, and these were excluded by
our search strategy. This represents a limitation
in the universal applicability of this data, which
could potentially be addressed by future inquiry.
In recent years, a number of techniques have
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been developed to assess the quality of
prospective randomized controlled trials. External validation and evaluation of these techniques continues to evolve [6,125–127]. The
primary goal of these scoring systems is to determine the likelihood of study bias. For this
meta-analysis, we chose to score the component trials using the method described by Jadad
et al. [6], because of its practical simplicity and
familiarity to the authors. Essentially, the quality scores of the articles included in this analysis were normally distributed, with overall
mean and median scores between two and
three (Fig. 1). The overall low quality scores of
many of the studies in this analysis is somewhat disturbing, however, raising the possibility of bias if lower quality studies favored one
or the other treatment options. Therefore, we
analyzed subsets that had been stratified according to their quality scores. The results in
these subsets did not appear to deviate notably
from the results of all studies combined, suggesting that study quality was not responsible
for the observed advantage of comparators
over aminoglycosides.
Some dismiss the use of meta-analyses entirely, noting that such studies are usually derived from combinations of heterogeneous
data. Optimally, meta-analyses should be
based on a series of homogenous studies, and
the overall study results should mimic the results of the component studies. Unfortunately,
such an ideal can rarely be realized. We employed one method of assessing study heterogeneity, by evaluating the variability of individual study results from the overall outcome
[4]. As applied to our results, this method identified a significant degree of heterogeneity.
Thus, the results of this meta-analysis need to
be interpreted with some degree of caution.
Nonetheless, some degree of trial heterogeneity is virtually inevitable, given the heterogeneous character of intra-abdominal infections
in general, which would be further amplified
by the numerous differences observed in overall study design and quality. Ultimately, future
large-scale trials of aminoglycosides for the antimicrobial therapy of intra-abdominal infections are unlikely to be performed. Thus, the
heterogeneous data obtained from trials published up to now will have to suffice for mak-
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ing recommendations with regard to the use of
these agents.
In 1984, Solomkin et al. [128] provided a critical evaluation and review of study design and
outcome reporting in trials of antimicrobials for
intra-abdominal infection, based on the evaluation of sixteen trials published in the early
1980’s. Some of the problems identified were
inclusion criteria that permitted enrollment of
patients with intra-abdominal contamination
but not intra-abdominal infection; exclusion
criteria that prevented enrollment of seriously
ill patients or patients with postoperative or recurrent infections; nonuniform reporting of infectious diagnoses; and nonuniform reporting
of outcomes, including the basis for designating patients as treatment failures.
Review of this larger and later collection of
studies unfortunately revalidates these findings of Solomkin et al. Of the 5,182 evaluable
patients, at least 1,100 (20%) had diagnoses potentially indicative of contamination but not
necessarily infection. Many exclusion criteria
that prevented enrollment of seriously ill patients were also encountered in this analysis.
The mean adult age in this analysis of 40 years
and the large number of patients with the appendix as the source of their intra-abdominal
infection imply that patients enrolled in these
studies were relatively younger and healthier
than many with intra-abdominal infections.
Thus, the applicability of these studies to an
older and sicker population is problematic.
Similarly, problems with regard to uniform reporting of infectious diagnosis and uniform criteria for reporting treatment outcome were evident in this analysis. With regard to this latter
problem, the available data were generally insufficient to permit any attempt at revising reported success and failure rates. Ultimately, it
was necessary to accept the investigator’s designated outcomes at face value, although the
differing definitions of success and failure
likely contributed to the observed heterogeneity [121].
As indicated, the overall analysis favored the
comparator agents over aminoglycosides. The
difference in OR increased when evaluating
only trials published since 1990. These findings
could indicate that it is newer comparator
agents that are more efficacious than amino-
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glycosides for therapy of intra-abdominal infections. However, there exists the possibility
that publication bias accounts in part for these
observations. Particularly in later years, studies favoring comparator regimens might have
been more likely to be published than studies
favoring aminoglycosides.
The likelihood of publication bias is difficult
to address without having access to the body
of unpublished data collected over the years.
However, the consistency of the results across
a variety of different subset analyses argues
against the possibility that publication bias was
solely responsible for the observed findings.
Perhaps some of the more interesting data
came from subset analyses of different comparator classes, including those utilizing somewhat older agents. With the exception of the
subset involving comparators from the penicillin class, all other regimens (carbapenem,
cephalosporin, monobactam, and oxa-betalactam), were favored over aminoglycoside-based
regimens. With comparators from the penicillin
class, the apparent advantage of aminoglycoside-based regimens was entirely due to studies utilizing ampicillin/sulbactam and amoxicillin/clavulanate, agents that have an inferior
spectrum of gram-negative coverage compared
to aminoglycosides. Elimination of these studies resulted in the finding that extended-spectrum penicillin regimens were significantly
more effective than aminoglycoside-based regimens. Another notable finding was that eliminating studies that employed comparator
agents now considered to lack adequate antianaerobic activity also shifted the odds ratio
more strongly in favor of the comparators.
Thus, it appeared that comparator regimens
having broad spectrum coverage of aerobic/
facultative anaerobic gram-negative organisms
and adequate anaerobic coverage consistently
demonstrated equivalence or actual superiority compared to aminoglycoside-based regimens. These observations strengthen the hypothesis that newer comparator regimens are
of potentially greater efficacy than aminoglycoside-based regimens for the therapy of intraabdominal infections.
Failure to achieve adequate serum aminoglycoside concentrations has been cited as one
possible explanation for study results favoring
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comparator regimens [114]. In this analysis,
there was no apparent difference in outcome
between those studies that reported monitoring of aminoglycoside serum concentrations
and those that did not. However, the actual
way in which monitoring was used to alter
aminoglycoside dosing regimens was not outlined consistently. Very few studies provided
any indication that prompt attainment of therapeutic aminoglycoside had been achieved,
and none of the studies employed once daily
dosing of aminoglycosides. Thus, the possibility that prolonged subtherapeutic concentrations of aminoglycosides contributed to increased failure rates remains a possibility.
In over 50% of the patients enrolled in these
trials, the appendix was the source of the intraabdominal infection. Although over 80% of
these patients were described as having complicated appendicitis, some of those patients
had gangrenous, but not perforated appendicitis. The remaining 20% of patients were only
described as having appendicitis, without any
other information being provided with regard
to the nature of the disease process. Thus many
of these patients with appendicitis may not
have required greater than 24 h of antibiotics
according to the Surgical Infection Society
guidelines of Bohnen et al [1]. Many patients
who had the appendix as their source of infection were enrolled in pediatric studies, and it
is likely that many adult patients with appendicitis were also relatively young and healthy.
It is notable that aminoglycosides were favored, although not significantly, in the studies in which all or a majority of the patients had
the appendix as the source of their infections.
Conversely, in the trials in which the majority
of patients did not have the appendix as the
source of infection, a significantly greater risk
of therapeutic failure was observed in patients
receiving aminoglycosides. Thus, the aminoglycoside-based regimens may actually have
been less efficacious in patients with more serious infectious processes.
The incidence of nephrotoxicity reported
with aminoglycoside use was two percent in
this study population. Although this seems reassuringly low, not all studies consistently reported nephrotoxicity, and little can be said
about the incidence of this complication in
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older, higher-risk patients. Nonetheless, the
costs of monitoring serum aminoglycoside concentrations for evidence of nephrotoxicity certainly add substantially to the burden of providing aminoglycoside therapy.
With regard to ototoxicity, only a tiny minority of studies reported any form of routine
monitoring for this complication. Six patients
were reported to have sustained some form of
ototoxic injury associated with aminoglycoside
therapy, although this was likely to have been
underreported. The development of aminoglycoside-induced ototoxicity, as opposed to
nephrotoxicity, is generally thought to be permanent, resulting in life-long disability. Thus,
it is somewhat disturbing that routine monitoring was not employed to detect this complication in the vast majority of trials. As part
of the assessment of the utility of these agents,
this type of toxicity needs to be considered.
In conclusion, this meta-analysis indicates
that aminoglycosides are no more efficacious,
and possibly less so than newer comparator
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agents for the treatment of patients with intraabdominal infections. Thus, these data refute
the notion that aminoglycoside-based regimens should be considered the “gold standard” for the treatment of these infections. Although the cost of these pharmaceuticals by
themselves may be low, the costs associated
with monitoring add appreciably to the overall expense of these regimens, and may negate
any cost advantage. In addition, these agents
have a narrow therapeutic index, with wellknown toxic side effects. Unfortunately,
prospective evaluation of toxicity, particularly
ototoxicity, has been poorly addressed in
many of these clinical trials. For all these reasons, we do not believe that aminoglycosides
should be utilized as first-line therapeutic
agents for the treatment of intra-abdominal infection. Their use should probably be reserved
for patients with severe allergic or anaphylactic reactions to most other classes of antibiotics,
or to those patients who have failed treatment
with other agents.
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APPENDIX: TRIAL DATABASE
N

N ev

AG agent

AG Combo Agent

Comp Agent

Comp Class

Comp
Comb Agent

Gripenberg

047

047

Tobra

Clinda

Cephalothin

Cephalosporin

Cephalexin

Stone 1982

249

155

Gent

Clinda

Cefotaxime

Cephalosporin

Berne*

237

130

Gent

Clinda

Cefamandole or
Cefperazone

Cephalosporin

Strom

156

156

Gent

Clinda

Moxalactam

oxa-betalactam

Baird

144

056

Gent

Clinda

Cefoperazone or
Cefperazone

Cephalosporin

Schentag

100

098

Tobra

Clinda

Moxalactam

oxa-betalactam

Biron

042

037

Tobra

Clinda

Cefotaxime

Cephalosporin

Busuttil

065

065

Gent

Clinda

Cefomandole

Cephalosporin

Stone 1984

099

099

Gent

Clinda

Ceftriaxone

Cephalosporin

Malangoni

170

112

Tobra

Clinda

Cefoxitin

Cephalosporin

Placebo

Yellin

197

105

Gent

Clinda

Ampicillin

PCN/B Lactam

sulbactam

Guerra

041

028

Gent

Clinda

Imipenem

Cilastatin

Lau

Author

Metronidazole

122

105

Gent

Metronidazole

Cefoxitin

Cephalosporin

Study Group of IAI 123

083

Gent

Clinda

Ampicillin

PCN/B Lactam

sulbactam

Gozenbach

093

093

Netilmicin

Clinda

Imipem

Carbapenem

Cilastatin

Leaper

045

043

Gent

Amp + Clinda

Imipem

Carbapenem

Cilastatin

Sirinek 1987

124

105

Gent

Clinda

Cefoxitin

Cephalosporin

Berne 1987

162

084

Gent

Clinda

Azetreonam

Monobactam

Stellato

105

059

Tobra

Clinda

Moxalactam

oxa-betalactam

Huizinga

100

088

Gent

Amp + Metronidazole

Cefotetan

Cephalosporin

Birolini

165

156

Tobra

Clinda

Azetreonam

Monobactam

Clinda

Fink

112

045

Gent

Clinda

Ticarcillin

PCN/B Lactam

Clavulanate

Schmitt

064

064

Netilmicin

Pen G + Metronidazole

Amoxicillin

PCN/B Lactam

Clavulanate

Poenaru

104

104

Tobra

Clinda or Metronidazole

Imipem

Carbapenem

Cilastatin

Solomkin**

290

162

Tobra

Clinda

Imipem

Carbapenem

Cilastatin

Bubrick

094

068

Tobra

Clinda

Ceftazidime

Cephalosporin

Clindamycin

Jauregui*

152

110

Gent

Clinda

Cefoperazone

Cephalosporin

sulbactam

Kooi*

100

100

Netilmicin

Metronidazole

Ceftazidime

Cephalosporin

Metronidazole

Swedish Study

271

184

Gent

Metronidazole

Pefloxacin

Quinolone

Metronidazole

Luke*

201

190

Netilmicin

Amp +Metronidazole

Ceftriaxone

Cephalosporin

Metronidazole

Meller

078

056

Gent

Clinda

Cefoxitin

Cephalosporin

Schropp

154

97

Gent

Amp + Clinda

Cefoxatime

Cephalosporin

Clinda

Williams

316

209

Tobra

Clinda

Azetreonam

Monobactam

Clinda

Sirinek 1991

099

099

Gent

Clinda

Ticarcillin

PCN/B Lactam

Clavulanate

Eckhauser

145

117

Gent/Tobra

Clinda

Imipem

Carbapenem

Cilastatin

Berne 1993

156

096

Gent

Clinda

Cefipime

Cephalosporin

Metronidazole

Polk

331

147

Gent

Clinda

Piperacillin

PCN/B Lactam

Tazobactam

Greenberg

076

076

Gent

Clinda

Cefoperazone

Cephalosporin

sulbactam

Hopkins

114

076

Amikacin

Clinda

Cefotetan

Cephalosporin

Barboza

067

062

Amikacin

Clinda

Azetreonam

Monobactam

Condon

177

127

Tobra

Clinda

Meropenem

Carbapenem

Dougherty

993

341

Gent

Clinda +/- Amp

Ticarcillin

PCN/B Lactam

Clavulanate

Shyr

077

076

Gent

Clinda

Piperacillin

PCN/B Lactam

Tazobactam

Berne 1996

228

129

Tobra

Clinda

Meropenem

Carbapenem

Wilson

427

191

Tobra

Clinda

Meropenem

Carbapenem

Ciftci (Ceftriaxone)

100

100

Tobra

PCN + Ornidazole

Ceftriaxone

Cephalosporin

Ciftci (Piperacillin)

100

100

Tobra

PCN + Clinda

Piperacillin

PCN/B Lactam

Torres

160

152

Gent

Metronidazole

Cefminox

Cephalosporin

Clinda

Clinda

Ornidazole

N, number of patients enrolled; N ev, number of evaluable patients; AG, aminoglycoside; AG s, number of evaluable
aminoglycoside treatment successes; AG #, total number of evaluable subjects on aminoglycoside arm; C s, number of
evaluable comparator treatment successes; C #, total number of evaluable subjects on comparator arm; Q, quality score; N
Appy, number of evaluable pediatric patients; PK 1 5 y, AG pharmacokinetic monitoring was reported; Year, year of
study publication; 1 C/Ana, comparator regimen with accepted anti-anaerobe efficacy; ORRF, odds ratio; CI, confidence
interval; Clinda, clindamycin; PCN, penicillin; Gent, gentamycin; Tobra, tobramycin; Amp, ampicillin.
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AG S

AG #

CS

C#

Q

N Appy

N Peds

PK 1 5 y

Year

1 5 C/Ana

ORRF

Lower CI

Upper CI

022

027

011

020

0

047

047

0

1981

0

0.278

0.075

1.031

065

077

065

078

1

026

000

0

1981

0

0.923

0.392

2.174

039

040

073

090

3

130

000

1

1982

0

0.110

0.014

0.859

045

079

065

077

0

037

000

0

1982

016

016

034

040

3

NR

NR

0

1983

0

0

0

037

049

036

049

2

013

000

1

1983

1

00.898

0.362

02.229

014

015

020

022

2

015

NR

0

1984

1

00.714

0.059

08.665

028

034

024

031

1

NR

NR

0

1984

0

00.735

0.217

02.486

038

052

039

047

2

20

000

0

1984

0

01.796

0.676

04.77

042

053

049

059

3

22

000

1

1985

1

01.283

0.496

03.32

038

038

059

067

4

105

000

1

1985

1

0

0

014

016

012

012

2

007

000

1

1985

050

052

051

053

3

105

NR

1

1986

1

01.020

0.138

07.525

036

037

040

046

3

NR

000

1

1986

1

00.185

0.021

01.613

043

046

042

047

2

053

000

1

1987

1

00.586

0.132

02.609

022

024

016

019

2

005

000

1

1987

1

00.485

0.072

03.247

049

051

050

054

3

105

NR

1

1987

1

00.510

0.089

02.914

027

028

054

056

2

084

000

1

1987

1

1

0.087

11.525

024

030

026

029

3

015

NR

1

1988

1

02.167

0.487

09.641

028

043

037

045

3

027

000

1

1989

1

02.478

0.922

06.659

069

080

066

076

2

078

NR

0

1989

1

01.052

0.419

02.641

016

025

015

020

3

010

00

1

1989

1

01.688

0.460

06.195

034

035

025

029

1

064

064

0

1989

1

00.184

0.019

01.746

034

052

041

052

1

NR

000

1

1990

1

01.973

0.821

04.744

057

081

067

081

2

039

000

1

1990

1

02.015

0.954

04.256

031

034

031

034

2

NR

000

1

1990

1

1

0.187

05.344

025

034

071

076

3

NR

000

1

1990

1

05.112

1.564

16.710

041

050

049

050

1

100

100

0

1990

1

10.756

1.308

88.473

094

104

064

080

3

115

000

1

1990

1

00.426

0.182

00.997

078

096

088

094

2

076

NR

0

1991

1

03.385

1.279

08.954

026

027

025

029

1

056

056

1

1991

1

00.240

0.025

02.301

042

047

048

050

05

097

097

0

1991

1

02.857

0.527

15.504

089

105

088

104

3

096

000

1

1991

1

00.989

0.466

02.099

036

043

048

056

1

099

NR

1

1991

1

01.167

0.387

03.514

059

064

051

053

2

018

NR

1

1992

1

02.161

0.402

11.619

038

046

047

050

3

096

000

1

1993

1

03.298

0.818

13.296

032

043

090

104

3

079

000

1

1993

1

02.210

0.910

005.364

015

029

033

047

3

024

000

1

1994

1

02.200

0.843

5.745

031

036

036

040

3

076

NR

1

1994

1

01.452

0.358

05.885

027

031

025

031

2

036

000

0

1994

1

00.617

0.156

02.447

056

063

059

064

4

046

000

1

1995

1

01.475

0.442

04.919

115

137

176

204

2

NR

124

1

1995

1

01.202

0.656

02.204

045

046

029

030

3

021

000

1

1995

1

00.644

0.039

10.713

060

066

058

063

5

129

000

1

1996

1

01.160

0.336

04.01

087

094

093

097

5

141

000

1

1997

1

01.871

0.529

06.613

046

050

048

050

2

100

100

0

1997

1

02.087

0.365

11.948

048

050

046

050

2

100

100

0

1997

1

00.479

0.084

02.743

070

076

075

076

2

095

000

1

2000

1

06.429

0.755

54.744

